For the four Her-2 positive patients, case 1 received SOX plus trastuzumab and PD-1 antibody pembrolizumab, case 2 received S-1 plus trastuzumab, case 3 received DCS regimen without trastuzumab because of allergy, and case 4 who was 85-years old received S-1 monotherapy without trastuzumab because of cardiac dysfunction. The gene discussed is ERBB2; the disease is allergic disease.